---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-020831"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:31:31.766515+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology reports positive Phase 2 KOMET-001 trial of ziftomenib in R/R NPM1-m AML

## Summary
- KOMET-001 achieved primary endpoint CR+CRh with statistical significance; benefit-risk profile encouraging.
- NDA submission to FDA for ziftomenib in R/R NPM1-m AML on track for Q2 2025.
- Plans to initiate two Phase 3 frontline trials (KOMET-017) in 2H 2025 with dual-primary endpoints for potential accelerated and full approval.
- Multiple data presentations expected in 2025 across ziftomenib, KO-2806, and tipifarnib programs.
- Collaboration with Kyowa Kirin continues for commercialization.

## SEC filing metadata
- accession: 0001193125-25-020831
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312525020831/0001193125-25-020831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312525020831/d886608d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-020831
- JSON: https://secwatch.observer/filing/0001193125-25-020831.json
- Plain text: https://secwatch.observer/filing/0001193125-25-020831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.